What Related Sciences does

Related Sciences (RS) is a data science-driven drug discovery venture studio founded in 2019 and headquartered in Denver, Colorado. The firm operates a proprietary AI/ML platform called Facets™, built on the RS Biomedical Atlas — a curated integration of 70+ public, private, and RS-proprietary biomedical datasets — to systematically rank approximately 250 million target-disease drug discovery opportunities across hundreds of proprietary risk-reward metrics. RS selects the top-ranking opportunities and bundles them into themed portfolios ("constellations") of 5–15 programs that are incubated inside dedicated portfolio companies. The first constellation was launched in July 2021 as Danger Bio, financed with $25.5M and staffed by 15 luminary scientific founders; it currently holds 15 preclinical programs (8 with valid chemical matter, 4 prioritized as lead franchises) targeting innate immunity pathways in cancer immunotherapy, autoimmunity, and inflammatory diseases. A second constellation has been announced but its therapeutic focus is not yet disclosed.

The firm executes a hub-and-spoke R&D model, partnering with eight major service and technology providers — most notably Evotec (partnership extended through 2030 to include covalent inhibitor discovery), Charles River (Logica AI platform), OpenBench (structure-based ML), DyNAbind, and Adimab — to convert fixed lab and overhead costs into variable expenses, with company-stated R&D cost reductions of 40%+ and capex elimination of 40–60% relative to traditional biotech. RS's go-to-market targets pharmaceutical and biotechnology acquirers seeking preclinical assets, with revenue mechanics encompassing portfolio equity ownership, R&D milestone payments, royalties, and program acquisition exits. A decentralized team science model engages more than 100 global scientists and 8 senior advisors drawn from former CEOs and R&D heads at Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca. RS is privately held, does not disclose revenue, and operates with a lean core team in the 1–10 employee band supplemented by this distributed scientific network.

Name

Related Sciences

Legal name

Related Sciences

Website

https://related.vc

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Related Sciences is a Denver-based, AI-native drug discovery venture studio that uses its proprietary Facets™ platform to rank 250 million target-disease opportunities and build themed preclinical portfolios (constellations) for eventual pharma acquisition, starting with Danger Bio.

Ownership category

akta.pro rank

Product category

Biotech Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Life Sciences & Biotech (R&D/Clinical) Staffing (BPACADAL)

Keywords

• Drug discovery platform
• Biotech venture creation
• AI drug prioritization
• Pharmaceutical R&D services
• Decentralized biotech research

Headquarters

HQ city

Denver

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biotech Company Creation and Portfolio Investment: Related Sciences builds and manages risk-optimized biotech companies (constellations/portfolios). The company centralizes and systematizes world-class capabilities to efficiently discover valuable new drugs and invests in unique portfolios of top-ranking programs. Revenue is generated through equity ownership in portfolio companies and eventual exits via acquisition or clinical progression.
2. R&D Partnerships and Milestones: Partnerships with R&D service providers and pharmaceutical companies generate milestone payments, royalties, and equity stakes. RS works with 8 major R&D partners including Evotec, which provides access to global network of cutting-edge laboratories, multi-modality screening capabilities, and thousands of expert drug discovery scientists.
3. Drug Program Acquisition/Exit: Earlier exits at lower valuations but with significantly smaller risks of failure, timelines, and capital requirements can offer enhanced overall risk-adjusted expected returns. RS optimizes program selection, team design, and business development strategies to increase possibilities of early acquisition interest in completed preclinical drugs while retaining full optionality to progress into clinic.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Related Sciences is a data science-driven drug foundry that uses its proprietary Facets™ AI/ML platform to systematically rank millions of target-disease drug discovery opportunities and build risk-optimized portfolios ("constellations") of drug programs. The company operates a decentralized team science model with 100+ global scientists and partners with CROs such as Evotec, Charles River, and OpenBench to advance preclinical programs, creating portfolio companies such as Danger Bio for eventual acquisition, partnership, or licensing by pharmaceutical companies.

Product overview

Related Sciences operates as a data science-driven drug discovery firm combining proprietary AI/ML technology with a decentralized R&D model. The core offering is the Facets™ Prioritization Engine, a machine learning platform that ingests 70+ biomedical datasets and systematically ranks millions of target-disease opportunities to identify the best drug discovery prospects. RS builds portfolio companies ('constellations') including Danger Bio (Constellation I focused on innate immunity), each comprising 5-15 top-ranking programs in ascendant therapeutic areas. The company utilizes a hub-and-spoke R&D model partnering with global service providers including Evotec, Charles River, and OpenBench. RS also develops and open-sources select bioinformatics tools (nxontology, ensembl-genes, articat, gce-github-runner) available on GitHub. RS currently has 15+ active preclinical drug programs across immunology and inflammatory biology.

Differentiator

Problem solved

Functional benefit

Brands

• Facets™: Proprietary machine learning platform that ingests all activities in global biomedicine and systematically predicts the best new drug discovery opportunities for every disease on an unbiased, quantified, and explainable basis.
• RS Biomedical Atlas
• Danger Bio

Products and services

• Facets™ Prioritization Engine Proprietary machine learning platform that ingests 70+ biomedical datasets and systematically ranks ~250 million target-disease drug discovery opportunities across hundreds of quantitative risk-reward metrics, identifying top programs with 4-5x higher likelihood of advancing beyond phase 2. Used to select and prioritize drug programs across RS portfolios.
• Danger Bio Flagship RS portfolio company focused on drugging the immune system's evolutionarily critical 'danger prevention' systems to treat root driver biology of immune-mediated diseases. Includes 15 preclinical programs across immune oncology, autoimmune/inflammatory diseases, and systemic lupus erythematosus with 15 scientific founders and 100+ drug discovery specialists.
• RS Constellation I (Danger Bio) First themed portfolio (constellation) of 5-15 top-ranking drug discovery opportunities in ascendant areas of research, launched in 2021 with Danger Bio as the operating vehicle. Targets innate immunity 'alarm system' biology with optimal risk-reward characteristics and portfolio-level risk diversification.
• RS Constellation II Second RS constellation themed portfolio of top-ranking drug discovery opportunities, expanding the firm's evergreen pipeline of new medicines beyond Constellation I.
• R&D Partnership Programs Integrated R&D partnership programs with leading CROs and technology providers (Evotec, Charles River, OpenBench, DyNAbind, Adimab) that execute preclinical discovery across multiple modalities under risk-sharing business models with milestone, royalty, and equity components.

Quantifiable outcome

• 40%+ reduction in R&D cost structures
• +5 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core and flagship/core.

• Charles River LaboratoriescoreStrategic or Co-development Partner · 14 September 2023Charles River and Related Sciences entered a multi-program collaboration to apply Logica (AI-powered drug solution from Charles River and Valo Health) across several previously undrugged targets in the RS portfolio. Logica combines AI/ML-enabled in silico discovery, high-powered DNA-encoded libraries, and traditional screening techniques. The partnership operates under a risk-sharing business model.
• OpenBenchcoreTechnology or Integration · 6 June 2023OpenBench provides structure-based machine learning platform for success-driven small molecule discovery. The collaboration applies OpenBench's discovery approach to current and future targets prioritized by the RS Facets™ platform. OpenBench bears the cost of virtual screening, custom synthesis, and experimental confirmation, with RS paying only for hits and leads meeting activity and developability criteria.
• Evotec SEflagship/coreStrategic or Co-development Partner · 9 February 2023Evotec is a key strategic partner providing integrated drug discovery services across the full R&D continuum. The partnership oversees a growing portfolio of more than 15 multi-modality drug discovery programs. The partnership was extended through 2030 to include Evotec's industry-leading capabilities in covalent inhibitor discovery, leveraging custom covalent libraries and novel screening approaches. Evotec is eligible to receive milestones, royalties, and a founding equity stake in all RS assets developed under the partnership.
• Danger Bioflagship/coreStrategic or Co-development Partner · 7 July 2021Danger Bio is Related Sciences' flagship portfolio company focused on drugging the immune system's 'danger prevention' systems to treat immune-mediated diseases. Launched in July 2021 with $25.5M initial financing, Danger Bio has 15 scientific founders from top academic institutions and 100+ drug discovery specialists. The company targets cancer immunotherapy, autoimmunity, and inflammatory diseases through modulation of innate immunity pathways.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Flagship Pioneering: Largest biotech venture creation firm (where RS co-founder Milwid previously worked). Spawns and funds multiple platform companies across therapeutic areas—structurally analogous to RS's constellation model but at vastly greater scale, with a deeper clinical pipeline track record.
• BridgeBio Pharma: Clinical-stage biotech using a portfolio approach of multiple genetically validated programs. Comparable to RS on the multi-program risk-diversified model and on centralized resource allocation across therapeutic-area programs.
• Roivant Sciences: Publicly traded biotech holding company that creates and incubates subsidiary biotech companies focused on specific therapeutic assets. Closest publicly traded analog to RS's multi-portfolio venture creation model with similar BD-driven exit strategy.

Direct peers

• Schrödinger, Inc. Computational drug discovery platform combining physics-based simulation, ML, and a SaaS offering used by pharma. Directly comparable to RS on the AI/computation-for-drug-discovery axis, with a publicly disclosed revenue base and partnered programs.
• Xaira Therapeutics: AI-first drug discovery company launched in 2024 with $1B+ from Foresite Labs and ARCH Venture Partners, focused on end-to-end AI-enabled therapeutic discovery. Most direct recent competitor to RS on AI-driven drug creation model and platform architecture.
• Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind, building computational models to predict drug behavior. Most well-capitalized peer pursuing target-disease prioritization with proprietary ML models, comparable to RS's Facets™ thesis.
• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to discover and develop therapeutics. Targets a similar workflow of data-driven target identification and partnered pharma programs, with comparable funding-stage profile.
• Recursion Pharmaceuticals: Publicly traded AI/ML-driven drug discovery company combining high-throughput biology, proprietary datasets, and ML models to identify novel therapeutics. Closest publicly comparable analog to RS's Facets™ platform approach, though at much larger scale and with clinical-stage assets.
• Atomwise: AI-driven small molecule drug design company using structure-based ML to discover novel compounds. Comparable to RS on the AI target/opportunity prioritization layer and on multi-program pharma partnership model.

Emerging players

• Genesis Therapeutics: AI-driven drug discovery company combining deep learning, physics, and chemistry to discover novel therapeutics. Emerging-stage peer with overlapping technology stack to RS's ML-driven prioritization approach, though smaller in headcount and pipeline scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Related Sciences